Andrii Buvailo, PhD

Science & Tech Communicator at www.AndriiBuvailo.com

Co-founder, BiopharmaTrend

Dr. Andrii Buvailo is a pharmaceutical industry analyst, tech scout and writer with a focus on artificial intelligence (AI) in drug discovery and biotech, digital transformation of pharma industry, and the advent of novel therapeutic modalities.

Andrii’s reports touch upon disruptive biotech startups, venture capital deals, drug discovery IPOs and platform companies. His articles were published on Forbes, and market research reports were referenced by some of the leading organizations (e.g. Deloitte).

Andrii is an ex-Enamine veteran, having served for the company as Director of E-commerce and Marketing for more than 8 years. Enamine is a global supplier of fine chemicals and compound libraries for the pharmaceutical industry.

Before venturing into the pharmaceutical industry and media entrepreneurship, Andrii used to work as a scientist. He holds PhD in Physical Chemistry, and has research experience in bioinorganic and supramolecular chemistry, thin polymer films, nanomaterials, and sensors.

Andrii is Ukrainian, currently based in Spain.

Recent articles from Andrii

A New Combination Strategy Shows Up to 31.3% Weight Loss in Preclinical Study

The modern obesity drug race has been defined by one word: incretins.

Blockbuster GLP-1 receptor agonists from companies like Novo Nordisk and Eli Lilly have reshaped both waistlines and Wall Street expectations. Drugs such as Semaglutide and Tirzepatide are …

FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss

The U.S. Food and Drug Administration has cleared Life Biosciences’ Investigational New Drug application for ER-100, allowing the Boston-based biotechnology company to begin a Phase 1 clinical trial in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).

This Company Claims World-First AI Models For Programmable Gene Insertion

That’s the headline from Basecamp Research this week, and if it holds up, it’s an important signal for genetic medicine field.

Neurotech Trends in 2025: When Use Cases Started Driving Design

Neurotechnology development in 2025 showed a shift from exploratory demonstration toward systems engineered around specific clinical and research uses. Across brain–computer interfaces, neuromodulation, diagnostics, and experimental neuroscience, design choices increasingly reflected where and how technologies are meant to operate, whether …

A 24-Hour Snapshot of AI Drug Discovery Across Pharma, Biotech, and Research

London-based Isomorphic Labs broke the news with yet another pharmaceutical partnership, announcing a new research collaboration with Johnson & Johnson’s Janssen Biotech unit aimed at AI-driven drug discovery across multiple targets and therapeutic modalities.

The Emergence of Diffusion Generative Models in Accelerating AI Drug Discovery

Recently, diffusion generative models, such as DALL-E 3, Midjourney or Imagen, have attracted considerable interest for their ability to create captivating and inventive images based on textual prompts. Researchers at MIT CSAIL, UW Institute for Protein Design …

Insilico Medicine Raises More Than US$290 Million in Hong Kong’s Largest Biotech IPO of 2025

AI-driven drug discovery company Insilico Medicine raised approximately HKD 2.28 billion (more than US$290 million) in its initial public offering on the Hong Kong Stock Exchange today, marking the largest biotech IPO in the city this year.

Novo Nordisk Scores Major Win as Oral Weight-Loss Pill Gets FDA Nod — and the Race for Obesity Drugs Just Got Hotter

In what feels like the moment biotech meets everyday life, the U.S. Food and Drug Administration has just approved the first daily oral weight-loss pill containing semaglutide, the same GLP-1 molecule behind household names like Wegovy and Ozempic. This …

10 Companies Shaping the Brain-Computer Interface Landscape: Invasive vs Non-Invasive BCI Technology

The brain–computer interface (BCI) technology domain is constantly progressing as researchers and companies collaborate to devise inventive solutions that connect the human brain with external devices. This expanding sector, driven by the need for better communication, rehabilitation, and augmented cognitive …

Why European Life Science’s Momentum May Finally Become Unstoppable

Living in Europe and watching the scene firsthand, it seems biotech here doesn’t revolve around a single gravitational center. There’s no Kendall Square-kind of place here, no San Francisco–style mega-cluster anywhere on the map. Instead, Europe operates like a distributed …